Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages
Church, Amy K., VanDerMeid, Karl R., Baig, Nisar A. , Baran, Andrea , Nowakowski, Grzegorz S. , Witzig, Thomas E. , Zent, Clive S.

Clinical and Experimental Immunology | August 26, 2015 | Volume: 183 | Issue: 1 | Pages: 90-101

10.1111/cei.12697 | PMID 26307241 Get It

Summary Unconjugated monoclonal antibodies (mAbs) are an important component of effective combination therapies for chronic lymphocytic leukaemia (CLL). Antibody-dependent phagocytosis (ADP) is a major mediator of mAb cytotoxicity, but there is limited knowledge of the determinants of ADP efficacy. We used macrophages derived in vitro from autologous circulating monocytes to test the effects of mAb structure and concentration, target : effector cell ratio, duration of co-incubation and CLL cell CD20 expression on ADP. Next-generation anti-CD20 mAbs (ofatumumab, ublituximab, obinutuzumab, ocaratuzumab) were significantly more effective at inducing ADP compared to rituximab, but none were as effective as the anti-CD52 mAb alemtuzumab. Ofatumumab (10 μg/ml) used as a representative next-generation anti-CD20 mAb achieved an ADP plateau at 3 h co-incubation with a target : effector ratio of 10 : 1 (mean = 2·1 CLL cells/macrophage, range = 1·5–3·5). At 0·156 μg/ml (the lowest concentration tested) ofatumumab ADP was significantly higher than alemtuzumab. However, ofatumumab-induced ADP did not increase significantly at higher mAb concentrations. We show that anti-CD20 mAb ADP efficacy is determined by the mAb characteristics, target : effector ratio and incubation time. We suggest that preclinical evaluation of anti-CD20 mAbs to understand the determinants of ADP could be useful in designing future combination therapies for CLL.
Genome-Wide Association Study of Prostate Cancer–Specific Survival
Szulkin, Robert , Whitington, Thomas, Aly, Markus , Grönberg, Henrik , Eeles, Rosalind A. , Easton, Douglas F. , Olama, Ali Amin Al , Benlloch, Sara, Muir, Kenneth , Giles, Graham G. , Southey, Melissa C. , FitzGerald, Liesel M. , Henderson, Brian E., Schumacher, Fredrick R. , Haiman, Christopher A. , Sipeky, Csilla , Tammela, Teuvo L.J. , Nordestgaard, Børge G. , Travis, Ruth C. , Neal, David E. , Donovan, Jenny , Hamdy, Freddie C. , Pashayan, Nora , Stanford, Janet L. , Thibodeau, Stephen N. , McDonnell, Shannon K. , Schaid, Daniel J. , Maier, Christiane, Vogel, Walther , Luedeke, Manuel, Herkommer, Kathleen , Kibel, Adam S. , Lubiński, Jan , Kluźniak, Wojciech , Cannon‐Albright, Lisa , Brenner, Hermann , Herrmann, Volker, Holleczek, Bernd , Sellers, Thomas A. , Lim, Hui-Yi, Kaneva, Radka , Mitev, Vanio , Teixeira, Manuel R. , Paulo, Paula , Maia, Sofia , Pandha, Hardev , Michael, Agnieszka , Batra, Jyotsna , Clements, Judith A. , BioResource, on behalf of the Australian Prostate Cancer, Albanes, Demetrius, Andriole, Gerald L. , Berndt, Sonja I., Gapstur, Susan M. , Giovannucci, Edward L. , Ma, Jing , Mondul, Alison M. , Stampfer, Meir J. , Stevens, Victoria L. , Weinstein, Stephanie J. , Trichopoulou, Antonia , Bueno-de-Mesquita, Bas H., Tjønneland, Anne , Cox, David G. , Mæhle, Lovise, Schleutker, Johanna , Lindström, Sara , Karlsson, Robert , Kote‐Jarai, Zsofia , Key, Tim , Pharoah, Paul D.P. , Khaw, Kay‐Tee , Cybulski, Cezary , Park, Jong Y. , Slavov, Chavdar , Spurdle, Amanda B. , Kierzek, Andrzej , BioResource, on behalf of the Australian Prostate Cancer, Berndt, Sonja I. , Chanock, Stephen Jacob , Hunter, David J. , Kraft, Peter , Marchand, Loı̈c Le , Penney, Kathryn , Wiklund, Fredrik E. , Giles, Graham G , Teixeira, Manuel R , Eeles, Rosalind A , Southey, Melissa C , Tjønneland, Anne , Donovan, Jenny L , Muir, Kenneth , Schleutker, Johanna , Travis, Ruth C , Pashayan, Nora , Cannon-Albright, Lisa A , Michael, Agnieszka , Brenner, Hermann , Batra, Jyotsna , Clements, Judith , Lubinski, Jan , McDonnell, Shannon K

Cancer Epidemiology, Biomarkers & Prevention | August 25, 2015 | Volume: 24 | Issue: 11 | Pages: 1796-1800

10.1158/1055-9965.epi-15-0543 | PMID 26307654 Get It

Abstract Background: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical. Methods: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR). Results: We observed no significant association between genetic variants and prostate cancer survival. Conclusions: Common genetic variants with large impact on prostate cancer survival were not observed in this study. Impact: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes. Cancer Epidemiol Biomarkers Prev; 24(11); 1796–800. ©2015 AACR.
PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
Joseph, Richard W. , Millis, Sherri Z. , Carballido, Estrella M., Bryant, David , Gatalica, Zoran , Bryce, Alan H. , Stanton, Melissa, Castle, Erik P., Ho, Thai H. , Stanton, Melissa L, Reddy, Sandeep K. , Vogelzang, Nicholas J. , Ho, Thai , Bryce, Alan H

Cancer Immunology Research | August 25, 2015 | Volume: 3 | Issue: 12 | Pages: 1303-1307

10.1158/2326-6066.cir-15-0150 | PMID 26307625 Get It

Abstract Monoclonal antibodies that target the programmed death-1 (PD-1)–programmed death ligand-1 (PD-L1) axis have antitumor activity against multiple cancers. The presence of sarcomatoid differentiation in renal cell carcinoma (RCC) is associated with resistance to targeted therapy and poor responses to IL2 immunotherapy. Given the aggressive nature of RCC with sarcomatoid differentiation and the exclusion of sarcomatoid histology from metastatic RCC clinical trials, less is understood regarding selection of therapies. Here, we characterized the PD-1/PD-L1 axis in RCC with sarcomatoid differentiation. We directly compared two PD-L1 antibodies and found concordance of PD-L1 positivity in 89% of tested RCCs with sarcomatoid differentiation. Coexpression of PD-L1 on neoplastic cells and the presence of PD-1–positive tumor-infiltrating lymphocytes were identified in 50% (13 of 26) of RCCs with sarcomatoid differentiation. In contrast, only 1 of 29 clear cell RCCs (3%) had concurrent expression of PD-L1 and PD-1 (P = 0.002). Our study suggests that RCC with sarcomatoid differentiation may express PD-1/PD-L1 at a higher percentage than RCC without sarcomatoid differentiation, and patients with these tumors may be good candidates for treatment with anti–PD-1/PD-L1 therapies. Cancer Immunol Res; 3(12); 1303–7. ©2015 AACR.
Anterior communicating artery aneurysm: Accuracy of CT angiography in determination of inflow dominance
Ahmed, Osama , Brown, Benjamin L. , Toms, Jaime, Gonzalez‐Toledo, Eduardo, Guthikonda, Bharat , Zhang, Shihao , Cuellar, Hugo

The Neuroradiology Journal | August 25, 2015 | Volume: 28 | Issue: 4 | Pages: 389-395

10.1177/1971400915594503 | PMID 26306932 Get It

Background Preoperative assessment of anterior communicating artery (AcoA) aneurysms with cerebral angiography is common, but not without risk. Computed tomography angiography (CTA) is a widely available imaging modality that provides quick acquisition, low morbidity, and low cost. One disadvantage is that it does not provide dynamic information. In this study, the authors sought to determine whether CTA alone can reliably predict the inflow dominance to an AcoA aneurysm. Methods Eighty-three patients with ruptured AcoA aneurysms were reviewed retrospectively. Only those patients with both preoperative CTA and cerebral angiogram were included, thus excluding six patients. Four independent observers reviewed the CTAs and attempted to identify the dominant A1. Additionally, three mathematical models were created to identify the dominant A1. These responses were compared to cerebral angiograms. Results Four observers were correct in judging the dominant A1 an average of 93% of the time. Seventeen cases were read incorrectly by only one of four observers, and three cases were read incorrectly by two observers. For cases with incorrect readings, the average percentage difference in A1 sizes was 19.6%. For cases read unanimously correct, the average percentage difference in A1 sizes was 42.7%. Mathematical model #3 correctly evaluated the dominant A1 in 97% of the cases. Conclusions This study found CT angiograms can be reliable in predicting the inflow dominance to the majority of AcoA aneurysms.
IgG4-Seronegative Autoimmune Pancreatitis and Sclerosing Cholangitis
Yadav, Anitha, Harrison, M. Edwyn , Kahn, Allon , Yadav, Anitha D

Case Reports in Gastrointestinal Medicine | August 25, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-6

10.1155/2015/591360 | PMID 26380127 Get It

IgG4-related disease is a relatively novel clinical entity whose gastrointestinal manifestations include type 1 autoimmune pancreatitis (AIP) and IgG4-associated sclerosing cholangitis. The presence of elevated serum IgG4 is suggestive but not essential for the diagnosis of type 1 AIP and is a pervasive feature of the proposed diagnostic criteria. The differential diagnosis of type 1 AIP includes malignant conditions, emphasizing the importance of a deliberate, comprehensive evaluation. Management of patients with a suggestive clinical presentation, but without serum IgG4 elevation, is difficult. Here we present three cases of IgG4-seronegative AIP and sclerosing cholangitis that responded to empiric steroid therapy and discuss approach considerations. These cases demonstrate the value of meticulous application of existing diagnostic algorithms to achieve a clinical diagnosis and avoid surgical intervention.
Improvements in Health Behaviors, Eating Self-Efficacy, and Goal-Setting Skills Following Participation in Wellness Coaching
Clark, Matthew M. , Bradley, Karleah L., Jenkins, Sarah M. , Mettler, Emily A., Larson, Brent G., Preston, Heather R., Liesinger, Juliette, Werneburg, Brooke L., Hagen, Philip T., Harris, Ann , Riley, Beth A., Olsen, Kerry D., Douglas, Kristin S. Vickers

American Journal of Health Promotion | August 25, 2015 | Volume: 30 | Issue: 6 | Pages: 458-464

10.4278/ajhp.140627-qual-304 | PMID 26305609 Get It

Purpose: This project examined potential changes in health behaviors following wellness coaching. Design: In a single cohort study design, wellness coaching participants were recruited in 2011, data were collected through July 2012, and were analyzed through December 2013. Items in the study questionnaire used requested information about 11 health behaviors, self-efficacy for eating, and goalsetting skills. Setting: Worksite wellness center. Participants: One-hundred employee wellness center members with an average age of 42 years; 90% were female and most were overweight or obese. Intervention: Twelve weeks of in-person, one-on-one wellness coaching. Method: Participants completed study questionnaires when they started wellness coaching (baseline), after 12 weeks of wellness coaching, and at a 3-month follow-up. Results: From baseline to week 12, these 100 wellness coaching participants improved their self-reported health behaviors (11 domains, 0- to 10-point scale) from an average of 6.4 to 7.7 ( p < .001), eating selfefficacy from an average of 112 to 142 (on a 0- to 180-point scale; p < .001), and goal-setting skills from an average of 49 to 55 (on a 16- to 80-point scale; p < .001). Conclusion: These results suggest that participants improved their current health behaviors and learned skills for continued healthy living. Future studies that use randomized controlled trials are needed to establish causality for wellness coaching.
Evaluation of pT 0 prostate cancer in patients undergoing radical prostatectomy
Moreira, Daniel M. , Gershman, Boris , Rangel, Laureano J. , Boorjian, Stephen A. , Thompson, R. Houston, Frank, Igor, Tollefson, Matthew K. , Gettman, Matthew T., Karnes, R. Jeffrey , Thompson, Robert Houston, Karnes, Robert Jeffrey

BJU International | August 25, 2015 | Volume: 118 | Issue: 3 | Pages: 379-383

10.1111/bju.13266 | PMID 26305996 Get It

Objective To evaluate the incidence, predictors and oncological outcomes of pT 0 prostate cancer ( PC a). Methods We conducted a retrospective analysis of 20 222 patients undergoing radical prostatectomy ( RP ) for PC a at the Mayo Clinic between 1987 and 2012. Disease recurrence was defined as follow‐up PSA >0.4 ng/mL or biopsy‐proven local recurrence. Systemic progression was defined as development of metastatic disease on imaging. Comparisons of baseline characteristics between pT 0 and non‐ pT 0 groups were carried out using chi‐squared tests. Recurrence‐free survival was estimated using the Kaplan–Meier method and compared using the log‐rank test. Results A total of 62 patients (0.3%) had pT 0 disease according to the RP specimen. In univariable analysis, pT 0 disease was significantly associated with older age ( P = 0.045), lower prostate‐specific antigen ( PSA ; P = 0.002), lower clinical stage ( P < 0.001), lower biopsy Gleason score ( P = 0.042), and receipt of preoperative transurethral resection, hormonal and radiation therapies (all P < 0.001). In multivariable analysis, lower PSA levels, lower Gleason score, and receipt of preoperative treatment were independently associated with pT 0 (all P < 0.05). Seven patients (11%) with pT 0 PC a developed disease recurrence over a median follow‐up of 10.9 years. All seven patients had preoperative treatment(s) and three had recurrence with a PSA doubling time of <9 months. Compared with non‐ pT 0 disease, pT 0 disease was associated with longer recurrence‐free survival ( P < 0.05). Only one (1.6%) patient with pT 0 disease developed systemic progression. Conclusions pT 0 stage PC a is a rare phenomenon and is associated with receipt of preoperative treatment and features of low‐risk PC a. Although pT 0 has a very favourable prognosis, some men, especially those who received preoperative treatment, experience a small but non‐negligible risk of disease recurrence and systemic progression.
There Is Nothing New Under the Sun
Aletti, Giovanni , Bristow, Robert E. , Chi, Dennis, Cliby, William A.

Journal of Clinical Oncology | August 25, 2015 | Volume: 33 | Issue: 30 | Pages: 3520-3520

10.1200/jco.2015.61.9536 | PMID 26304883 Get It

Diabetes and depression: does worsening control of diabetes lead to poorer depression outcomes?
Angstman, Kurt B. , Flinchbaugh, Robert T., Flinchbaugh, Katherine, Meunier, Matthew R. , Angstman, Gregory L., Angstman, Kurt

Journal of Evaluation in Clinical Practice | August 25, 2015 | Volume: 22 | Issue: 1 | Pages: 98-100

10.1111/jep.12443 | PMID 26303566 Get It

AbstractRationale, aims and objectivesThe relationship between diabetes and depression is complex. The aim of this study was to study the impact of diabetic control in depressed primary care patients with diabetes on clinical remission of their depression at 6 months.MethodsThis study was a retrospective chart review analysis of 145 adult patients diagnosed with either major depressive disorder or dysthymia and had a score of 10 or greater on the PHQ‐9. The dependent variable for this study was depression remission at 6 months. The independent variables for this study were age, gender, marital status, race, BMI and HbA1c level within 2 months prior to the time of depression diagnosis.ResultsMultiple logistic regression modelling demonstrated that initial diabetic control or obesity were not independent predictors of depression remission at 6 months after index date. Also, the odds for the diabetes being in control (HbA1c <8.0%) after 6 months was only associated with being in control at baseline (OR 5.549, CI 2.364–13.024, P < 0.001).ConclusionsBaseline diabetic control does not appear to be an independent predictor for depression outcomes at 6 months. The best predictor of diabetic control after the diagnosis of depression was previous control of diabetes.
Patient-Inspired Engineering and Nanotechnology
Öklü, Rahmi , Weiss, Paul S. , Khademhosseini, Ali , Oklu, Rahmi , Weiss, Paul S

ACS Nano | August 25, 2015 | Volume: 9 | Issue: 8 | Pages: 7733-7734

10.1021/acsnano.5b05000 | PMID 26305171 Get It